title: Caenorhabditis elegans neuromuscular junction: GABA receptors and ivermectin action.
abstract: The prevalence of human and animal helminth infections remains staggeringly high, thus urging the need for concerted efforts towards this area of research. GABA receptors, encoded by the unc-49 gene, mediate body muscle inhibition in Caenorhabditis elegans and parasitic nematodes and are targets of anthelmintic drugs. Thus, the characterization of nematode GABA receptors provides a foundation for rational anti-parasitic drug design. We therefore explored UNC-49 channels from C. elegans muscle cultured cells of the first larval stage at the electrophysiological and behavioral levels. Whole-cell recordings reveal that GABA, muscimol and the anthelmintic piperazine elicit macroscopic currents from UNC-49 receptors that decay in their sustained presence, indicating full desensitization. Single-channel recordings show that all drugs elicit openings of ∼2.5 pA (+100 mV), which appear either as brief isolated events or in short bursts. The comparison of the lowest concentration required for detectable channel opening, the frequency of openings and the amplitude of macroscopic currents suggest that piperazine is the least efficacious of the three drugs. Macroscopic and single-channel GABA-activated currents are profoundly and apparently irreversibly inhibited by ivermectin. To gain further insight into ivermectin action at C. elegans muscle, we analyzed its effect on single-channel activity of the levamisol-sensitive nicotinic receptor (L-AChR), the excitatory receptor involved in neuromuscular transmission. Ivermectin produces a profound inhibition of the frequency of channel opening without significant changes in channel properties. By revealing that ivermectin inhibits C. elegans muscle GABA and L-AChR receptors, our study adds two receptors to the already known ivermectin targets, thus contributing to the elucidation of its pleiotropic effects. Behavioral assays in worms show that ivermectin potentiates piperazine-induced paralysis, thus suggesting that their combination is a good strategy to overcome the increasing resistance of parasites, an issue of global concern for human and animal health.
authors.affiliation: Instituto de Investigaciones Bioquímicas de Bahía Blanca-Universidad Nacional del Sur, Consejo Nacional de Investigaciones Científicas y Técnicas, Bahía Blanca, Buenos Aires, Argentina.
authors.forename: Guillermina
authors.initials: G
authors.lastname: Hernando
authors.affiliation: Instituto de Investigaciones Bioquímicas de Bahía Blanca-Universidad Nacional del Sur, Consejo Nacional de Investigaciones Científicas y Técnicas, Bahía Blanca, Buenos Aires, Argentina.
authors.forename: Cecilia
authors.initials: C
authors.lastname: Bouzat
mesh_terms: D000818:Animals; D000977:Antiparasitic Agents / Q000494:pharmacology*; D017173:Caenorhabditis elegans / Q000378:metabolism*; D029742:Caenorhabditis elegans Proteins / Q000378:metabolism*; D006801:Humans; D007559:Ivermectin / Q000494:pharmacology*; D009469:Neuromuscular Junction / Q000378:metabolism*; D018079:Receptors, GABA / Q000378:metabolism*; D009435:Synaptic Transmission / Q000187:drug effects / Q000502:physiology
chemical_list: D000977:Antiparasitic Agents; D029742:Caenorhabditis elegans Proteins; D018079:Receptors, GABA; D007559:Ivermectin
references.citation: J Neurosci. 2011 Mar 9;31(10):3662-9
references.pmid: 21389221
references.citation: Trends Parasitol. 2012 May;28(5):176-81
references.pmid: 22424638
references.citation: Mol Pharmacol. 2010 Aug;78(2):198-204
references.pmid: 20463059
references.citation: Invert Neurosci. 2007 Dec;7(4):219-26
references.pmid: 17952476
references.citation: Vet J. 2002 Mar;163(2):161-7
references.pmid: 12093191
references.citation: J Neurosci. 2003 Apr 1;23(7):2591-9
references.pmid: 12684444
references.citation: Front Mol Neurosci. 2012 May 07;5:60
references.pmid: 22586367
references.citation: Neuropharmacology. 2011 Feb-Mar;60(2-3):520-8
references.pmid: 21093460
references.citation: J Neurochem. 2010 Jun;113(5):1113-22
references.pmid: 20180830
references.citation: Exp Parasitol. 1993 Aug;77(1):88-96
references.pmid: 8344410
references.citation: Trends Parasitol. 2005 Nov;21(11):530-2
references.pmid: 16126457
references.citation: Philos Trans R Soc Lond B Biol Sci. 1976 Aug 10;275(938):327-48
references.pmid: 8806
references.citation: Int J Biochem Cell Biol. 2012 Feb;44(2):335-40
references.pmid: 22094187
references.citation: Neuroscience. 2000;101(3):785-91
references.pmid: 11113327
references.citation: Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2674-9
references.pmid: 10716995
references.citation: PLoS Negl Trop Dis. 2012;6(11):e1883
references.pmid: 23133688
references.citation: J Neurosci. 1999 Jul 1;19(13):5348-59
references.pmid: 10377345
references.citation: Exp Parasitol. 2012 Jul;131(3):304-9
references.pmid: 22575734
references.citation: Neuron. 2002 Feb 14;33(4):503-14
references.pmid: 11856526
references.citation: Curr Pharm Biotechnol. 2012 May;13(6):866-72
references.pmid: 22039785
references.citation: Vet Parasitol. 2012 Apr 30;185(2-4):201-9
references.pmid: 22075040
references.citation: Biophys J. 1991 Aug;60(2):424-32
references.pmid: 1717017
references.citation: J Physiol Paris. 2012 Jan;106(1-2):23-33
references.pmid: 21995938
references.citation: Parasitology. 1996 Feb;112 ( Pt 2):247-52
references.pmid: 8851865
references.citation: J Biol Chem. 2011 Jan 28;286(4):2550-8
references.pmid: 20966081
references.citation: Br J Pharmacol. 1989 Nov;98(3):841-50
references.pmid: 2556203
references.citation: Proc Natl Acad Sci U S A. 1980 Oct;77(10):6211-5
references.pmid: 6255481
references.citation: Recent Pat CNS Drug Discov. 2007 Jun;2(2):99-106
references.pmid: 18221220
references.citation: Anesthesiology. 2011 Dec;115(6):1338-48
references.pmid: 21881491
references.citation: Trends Pharmacol Sci. 2012 Aug;33(8):432-41
references.pmid: 22677714
references.citation: Mol Pharmacol. 2012 Sep;82(3):550-60
references.pmid: 22734069
references.citation: Mol Pharmacol. 2007 May;71(5):1407-15
references.pmid: 17314321
references.citation: Mol Biochem Parasitol. 1984 Oct;13(2):213-25
references.pmid: 6096713
references.citation: Nature. 1993 Jul 22;364(6435):337-41
references.pmid: 8332191
references.citation: Br J Pharmacol. 1985 Feb;84(2):445-61
references.pmid: 2579701
references.citation: Br J Pharmacol. 2003 Mar;138(5):883-93
references.pmid: 12642390
references.citation: Br J Pharmacol. 2005 Feb;144(4):502-9
references.pmid: 15655525
references.citation: Parasitology. 1990 Oct;101 Pt 2:265-71
references.pmid: 2175874
references.citation: Biochem Pharmacol. 2009 Oct 1;78(7):836-43
references.pmid: 19549506
references.citation: J Biol Chem. 2012 Nov 23;287(48):40224-31
references.pmid: 23038269
references.citation: PLoS One. 2011;6(7):e22390
references.pmid: 21818319
references.citation: Mol Neurobiol. 2009 Dec;40(3):236-52
references.pmid: 19859835
references.citation: Trends Pharmacol Sci. 2010 Apr;31(4):161-74
references.pmid: 20096941
references.citation: Mol Pharmacol. 2005 Nov;68(5):1475-83
references.pmid: 16118362
references.citation: Parasitol Int. 2013 Dec;62(6):591-8
references.pmid: 23707730
references.citation: Parasitology. 2000;121 Suppl:S133-46
references.pmid: 11386685
references.citation: J Biol Chem. 2011 Dec 23;286(51):43913-43924
references.pmid: 22033924
references.citation: Br J Pharmacol. 1982 Oct;77(2):255-65
references.pmid: 7139188
references.citation: Invert Neurosci. 2012 Jun;12(1):3-12
references.pmid: 22430311
references.citation: Lancet. 1994 Mar 19;343(8899):739
references.pmid: 7907715
references.citation: Trends Neurosci. 2004 Jul;27(7):407-14
references.pmid: 15219740
references.citation: Biophys J. 2011 Apr 20;100(8):1977-85
references.pmid: 21504734
references.citation: EMBO J. 2009 Sep 2;28(17):2636-49
references.pmid: 19609303
references.citation: Nature. 2011 Jun 2;474(7349):54-60
references.pmid: 21572436
references.citation: Regul Toxicol Pharmacol. 2007 Apr;47(3):257-60
references.pmid: 17234315
references.citation: Mol Pharmacol. 1998 Feb;53(2):283-94
references.pmid: 9463487